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Summary Cyclic AMP Binding Proteins (cAMP-BP) levels have been measured by means of a competitive
binding assay in the cytosols of 50 human colorectal cancers. These levels have been related to those in
mucosa both adjacent to and distant from the tumour in the same patients. Cyclic AMP-BP were higher in
tumour than in either adjacent (P<0.000001) or distant mucosa (P<0.00001). Binding of cAMP in adjacent
mucosa was lower than that in distant mucosa (P<0.0001). There was no significant difference in the level of
binding between tumours arising from different sites in the colon and binding was not related to age or sex of
the patient. However, binding was higher in Dukes' B than Dukes' C cancers (P<0.005). There was also a
trend for cAMP binding levels to be higher in moderately differentiated than in poorly differentiated cancers
(P = 0.07). Thus cAMP-BP appear to be over-expressed in human colorectal cancers and levels are related to
the stage and grade.
Cyclic adenosine 3',5'-monophosphate (cAMP) functions as a
secondary messenger for a wide range of hormones releasing
factors and drugs. The cAMP signalling system also interacts
with other signalling pathways that are used by locally-acting
growth factors (Olashaw & Pledger, 1988) to bring about
co-ordinated control of basic cell processes such as prolifera-
tion and differentiation. Cyclic AMP exerts all its known
effects through binding to and activating a specific cAMP-
dependent protein kinase, also known as Protein Kinase A
(PK-A) (Taylor et al., 1989). PK-A is a tetrameric holoen-
zyme comprising two regulatory units (R), and two catalytic
units (C). R units, also known as cAMP binding proteins
(cAMP-BP) act as pseudosubstrate for the C units and so
prevent them from carrying out phosphorylation within the
cell (Shenolikar, 1988). Activation of PK-A follows binding
of cAMP to R units and their dissociation from the C unit.
As well as leading to protein phosphorylation, activation
PK-A also brings about changes in expression of cAMP
dependent genes, although the exact mechanisms are, as yet,
unclear (Roesler et al., 1988). Conventionally, cAMP has
been considered a negative signal to cellular proliferation
although stimulatory effects have been described depending
on the cell type, phase in the cell cycle and presence of other
growth factors (Dumont et al., 1989). Cyclic AMP analogues
have been shown to inhibit the growth and promote the
differentiation of a number of human cancer cell lines in vitro
including those derived from colorectal cancer (Ally et al.,
1988). In animal studies the production of colonic tumours
by chemical carcinogens has been associated with decreased
levels of PK-A activity (DeRubertis & Craven, 1980). Fur-
thermore, cAMP and cAMP-dependent protein kinase levels
have been reported to be lower in human colorectal cancers
and villous adenomas than in normal mucosa (Alexandrov et
al., 1986). By contrast, in breast cancer cAMP-BP levels are
of independent prognostic significance (Miller et al., 1990)
with higher levels of binding being associated with reduced
disease free interval and decreased survival. The aim of this
study was to determine the levels of cAMP-BP in human
colorectal cancers and related mucosa and to correlate these
levels to known prognostic factors; namely stage and grade.
Methods
Patients
Specimens were obtained from 50 patients undergoing elec-
tive surgery for colorectal cancer from which sufficient ma-
terial was available for study after histological confirmation
of disease. The series comprised 23 men (average age 65.5
years ± s.d. 11.1) and 27 women (average age 70.6 years
± s.d. 9.4). The distribution of tumours of site, Dukes stage
and histological grade is shown in Table I.
Collection ofspecimens
Specimens of colorectal cancer and related mucosa were
obtained fresh from the operating theatre and kept on ice
until processing. Tissue was removed from the tumour and
from adjacent (as near to the tumour as possible without
contamination with tumour tissue) and distant areas (greater
than 5 cm from the tumour edge) of macroscopically normal
mucosa. When sampling tumour, tissue was removed towards
the edge and attempts were made to avoid obviously necrotic
or haemorrhagic areas. Tissue was stored at - 70°C until use.
The operative specimen underwent routine histopathology
and histology of the individual specimens assayed was also
performed.
Preparation ofcytosols
All procedures were performed at 0-4°C. Approximately
200 mg of tissue was homogenised (Silverson) in 1:10 w/v of
tissue buffer (pH 7.5) containing 20 mM Tris, 2 mM magnes-
ium chloride, I mM calcium chloride, 10 mM calcium chlor-
ide, 16 mM HCI and 100 KIU Aprotinin ml-' (Bayer UK
LTd). The homogenate was centrifuged at 105,000g for I h
(Sorval Superspeed 50) and the supernatant removed and
used as cytosol.
Determination ofprotein content ofcytosols
A spectrophotometric method using Coomassie Brilliant Blue
(Sigma) was employed (Bradford, 1976). Bovine serum
albumen (Sigma) was used as a standard.
Cyclic AMP binding assay
The cytosol (50 gl) was incubated in duplicate overnight at
4°C with 100yl1 of 25 nm (to give a final concentration of
10 nM) 5'8-3H-cAMP (Sp. Ac. 44.5-59 Ci mmol-' Amer-
sham International) and 100 gl of assay buffer (55 mm potas-
sium phosphate with the fresh addition of 11 mM theophyl-
line) containing increasing final concentrations (0, 10, 20, 40,
80, 10,000 nM) or radio-inert cAMP (Sigma). Bound and free
cAMP were then separated by filtration (Millipore HAWP
0.45 gm). Filters were washed in assay buffer containing
10 mM magnesium chloride and allowed to dry. Scintillant
(5 ml, NE-260 Nuclear Enterprises) was added to each vial
and incubated for 2 h at 37°C. The vials were then counted in
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Table I Colorectal cancers by sex ofpatient, site, Dukes' stage and grade
Site Dukes' stage Histological grade
Site Male Female Stage Male Female Grade Male Female
CA 3 7 A 2 - Moderate 17 19
AC 2 1 B 15 17 Poor 6 8
TC - 1 C 6 10
DC 2 1
SI 5 13
RE 11 4
CA = caecum, AC = ascendingcolon,TC = transversecolon, DC = descendingcolon;
SI = sigmoid, RE = rectum.
4000-
.c 3500-
0) +-'
Co
._ "Q
*' o 3000-
a-0 cx
>
0 2500-
20E
E 2000-
E
CD
o 0 a
E -
c CO
cn>
La0co cc E
._ Q-
C
.)
'- c< E
1500 .IX I I
Tumour Mucosa
(periphery) (adjacent)
Mucosa
(distant)
Figure 1 Comparison of cAMP binding in 50 colorectal cancers
and related adjacent and distant mucosa. 0 represent means and
- the standard error. Means of all three samples statistically
different by one-way ANOVA, P<0.0001.
a Tricarb liquid scintillation counter (Packard). Results were
analysed by Scatchard analysis (Scatchard, 1949) and ex-
pressed as fmol cAMP bound per mg cytosol protein.
Results
Cyclic AMP binding in tumour and mucosa
Binding was detected in all specimens assayed. However,
binding in the tumour (3366 ± s.e. 228, range 1012-8910)
was significantly higher (P<0.000001 paired t-test) than
binding in both adjacent mucosa (2298 ± s.e. 129, range
968-3546) and distant mucosa (2631 ± s.e. 146, range
1000-4807) (P<0.00001 paired t-test). By one-way ANOVA
binding levels in all three specimens were significantly
different from each other (P<0.0001). In addition, binding
in the three specimens types were strongly inter-correlated.
These data are presented in Figure 1, 2, 3 and 4.
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Figure 2 Correlation of cAMP binding in colorectal cancer and
adjacent mucosa. 50 paired samples. Correlation coefficient
r=0.64, P<0.0001.
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Figure 3 Correlation of cAMP binding in colorectal cancer and
distant mucosa. 50 paired samples. Correlation coefficient
r=0.77, P<0.0001.
Age and sex ofpatients
There was no correlation between the age of the patient and
the tumour level of cAMP (data not shown). Neither was
binding in tumours from male patients (3563 ± s.e. 333)
significantly different from that in tumours from female
patients (3201 ± s.e. 318).
Site oftumour
Cyclic AMP binding in both tumours and adjacent and
distant mucosa was unrelated to the site of origin of that
tumour within the colorectum (data not shown).
Stage oftumour
Dukes' B tumours (3858 ± 294, range 1012-8910) had signi-
ficantly higher binding (P<0.005 unpaired t-test) than
Dukes' C tumours (2321 ± 205, range 1024-3871). The two
Dukes' A tumours in the series had binding levels of 5619
and 2154. Adjacent and distant mucosa related to Dukes' B
tumours also had significantly higher binding (P<0.05 and
P<0.001 respectively) than the corresponding samples from
mucosa related to Dukes' C tumours (Figure 5).
Grade oftumour
With increasing de-differentiation there is a decrease in
tumour cAMP binding although this does not attain statis-
tical significance. Moderately differentiated tumours (n = 36,
3624 ± 314, range 1012-8910) had higher (P = 0.07) binding
than those which were poorly differentiated (n = 14,
2708+ 347, range 1415-4136) (Figure 6).
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Correlation of cAMP binding in colorectal cancer and
mucosa. 50 paired samples. Correlation coefficient
P <0.0001.
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Figure 5 Comparison of cAMP binding in colorectal cancers of
different Dukes' stage. 0 represent means and - the standard
error. Thirty-two Dukes' B tumours and 16 Dukes' C tumours.
Binding in Dukes' B tumours was higher than binding in Dukes'
C tumours (P<0.005 by unpaired t-test). Both adjacent and
distant mucosa from colons supporting the growth of Dukes' B
tumours had higher binding than that from colons supporting the
growth of Dukes' C tumours (P<0.05 and P<0.0001 by
unpaired t-test respectively).
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Figure 6 Comparison of cAMP binding in tumours of different
histological grade. 0 represent means and
- the standard error.
Thirty-six tumours graded as moderately differentiated have
higher binding than 14 tumours graded as poorly differentiated
(P 0.07 by unpaired t-test).
Discussion
This study is the first to show that human colorectal cancers
have markedly elevated levels of cAMP binding proteins
when compared to either adjacent or distant histologically
benign mucosa. By contrast Alexandrov et al. (1986) reported
low levels of cAMP and PK-A activity in villous adenomas
and colorectal cancers when compared to normal mucosa.
However, raised cAMP-BP levels may not reflect increased
PK-A activity. Although the proportion of regulatory to
catalytic sub-units is often been assumed to be equal, over-
expression of abnormal cAMP binding proteins has been
reported (Prashad, 1982).
This study also demonstrates that levels of cAMP binding
in mucosa immediately adjacent to the tumours is lower than
that in distant mucosa. Thus there appears to be a zone of
depressed binding surrounding the tumour. It is possible that
the tumour is releasing some, as yet unidentified, locally
acting factor that is suppressing the surrounding mucosa. In
this respect it has been shown that colorectal cancers are
capable of secreting biologically active factors; for example
Pommier (1988) has demonstrated the release of an autocrine
growth factor by colorectal cancer cell lines. Alternatively, a
'transitional' mucosa surrounding colorectal cancers has been
described characterised by inflammatory cell infiltrate, goblet
and basal cell hyperplasia, mucosal ulceration and ischaemia
(Lee, 1988). Such an abnormal mucosa may have different
levels of cAMP binding per se. Cyclic AMP binding was
higher in tumours of earlier stage and grade with levels
falling as the tumour becomes more malignant. This is the
first report of a relationship between cAMP binding protein
expression and stage and grade of cancer. However, in breast
cancer, although there is no correlation between cAMP bind-
ing protein levels and stage and grade of disease, high levels
ofbinding proteins are ofindependent prognostic significance
in predicting poor outcome in terms of disease-free interval
and overall survival (Miller et al., 1990). Despite stage and
grade being general indicators of overall prognosis in colo-
rectal cancer (Wiggers et al., 1988), they are of limited use in
predicting outcome for individual patients (Fielding et al.,
1986) reflecting the differing biology and behaviour of indi-
vidual tumours. Likewise there is an almost 10-fold variation
in cAMP binding between tumours in this series and a
considerable overlap between Dukes' B (1012-8910) and
Dukes' C (1024-3871) groups. It is intended to follow this
group of patients to determine whether cAMP binding levels
are related to overall prognosis.
Interestingly, cAMP binding in non-neoplastic mucosa
from colons supporting Dukes' B tumours was significantly
higher than that found in mucosa from colons with Dukes' C
lesions. Thus stage dependent differences are present not only
within malignant tissue, but also in benign mucosa adjacent
to and distant from the cancer. These results indicate the
possibility of pan-colonic changes in cAMP binding. Abnor-
malities in colonic mucosal proliferation have been frequently
described in persons at increased risk of and in patients with
colorectal cancer (Lipkin, 1988). Furthermore, increases in
pan-colonic proliferative indices have been linked to the
presence and size of colonic adenomas and cancers (Terpstra
et al., 1987). Lower levels PK-A activity have been reported
in the proliferative compartment of colonic crypts (Schwartz
et al., 1988) and it may be that levels of cAMP binding
found in this study reflect overall proliferative changes.
Because of the very significant differences in the level of
expression of cAMP binding proteins between benign and
malignant tissue in this study, it is relevant to discuss briefly
the biology of cAMP binding proteins as it might relate to
the malignant process. In addition to their role in regulating
the kinase activity of PK-A, it has been postulated that
cAMP binding proteins might have independent function in
the regulation of cAMP gene transcription (Zwelling, 1988).
For example, cAMP binding proteins have homology with
DNA binding proteins and an initial report appeared to
show that they possessed intrinsic Topoisomerase I activity
(Constantinou et al., 1985). However, more recently it has
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been possible to separate cAMP binding proteins from Topo-
isomerase activity (Shabb & Granner, 1988, Hunzicker-Dunn
et al., 1989). Despite these conflicting findings, cAMP bind-
ing proteins have been shown to enter the nucleus following
PK-A activation (Tagliaferri et al., 1988) and to associate
with transcriptionally active chromatin during changes in
gene expression (Sikorska et al., 1988). Furthermore, cAMP
has been shown to enhance the ability of cAMP binding
proteins to bind oligonucleotide in a sequence-selective man-
ner (Wu & Wang, 1989). Thus although many of the changes
in cAMP dependent gene expression are due to the phos-
phorylation and activation of transcription factors by the
catalytic subunit of PK-A (Ziff, 1990) there is increasing
evidence that the regulatory cAMP binding subunits play an
independent or modulating role. Interestingly, the ability of
cAMP analogs to reverse the malignant phenotype of a
number of cell lines including those derived from human
colorectal cancer is associated with changes in the expression
of cAMP binding proteins and the movement of binding
proteins in to the nucleus (Cho-Chung et al., 1989). Cyclic
AMP binding proteins may therefore have an important role
in controlling the expression of genes involved in develop-
ment of the malignant state.
Irrespective of their mechanism of action, the results pre-
sented in this paper clearly demonstrate that an abnormality
within the cAMP signalling system is associated with the
development and possibly the progression of human colorec-
tal cancers. This is the first report of such a finding and
indicates that a defect in cellular control normally exerted
through the cAMP system may be involved in colorectal
carcinogenesis.
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